AUTOLUS THERAPEUTICS PLC
AUTLNASDAQTrading Snapshot
- Day Range
- $1,004.34 – $1,020.77
- 52-Week Range
- $1.18 – $2.58
- Volume
- $2.35B
- Avg Volume
- $3.04B
- Shares Outstanding
- 266.1M
- Next Earnings
- Nov 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $76M
- Last Q Revenue
- $46M
- P/E Ratio
- -1.8
- P/S Ratio
- 4.2x
- EPS (TTM)
- $-1.05
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.0%
Why Investors Own AUTL
- ✓High-growth profile — revenue up +21.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
AUTOLUS THERAPEUTICS PLC
AUTL
StockOtter · stockotter.spaceAbout AUTOLUS THERAPEUTICS PLC
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
AUTOLUS THERAPEUTICS PLC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift AUTL price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
AUTOLUS THERAPEUTICS PLC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.